![Yihai Cao](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ursprung des Netzwerks ersten Grades von Yihai Cao
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
ClanoTech AB
![]() ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden.
3
| Holding Company | Pharmaceuticals: Major | 3 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Yihai Cao
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Rosetta Capital Ltd.
![]() Rosetta Capital Ltd. Investment ManagersFinance Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London. | Investment Managers | Private Equity Investor | |
MISSION Therapeutics Ltd.
![]() MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
AstraZeneca AB
![]() AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Pharmacia & Upjohn Co. LLC
![]() Pharmacia & Upjohn Co. LLC Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Pharmacia & Upjohn Co. LLC is a company that manufactures and supplies pharmaceutical goods. The company is based in Bingham Farms, MI. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Pharmacia Upjohn | Corporate Officer/Principal | ||
Astra Arcus AB | Corporate Officer/Principal | ||
Oxford Science Enterprises PLC
![]() Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | Investment Managers | Consultant / Advisor | |
Carrick Therapeutics Ltd.
![]() Carrick Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Carrick Therapeutics Ltd. manufactures cancer therapeutics. The company is headquartered in Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member | |
Nucleome Therapeutics Ltd.
![]() Nucleome Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nucleome Therapeutics Ltd. develops small molecular drugs for autoimmune diseases. The company was founded by Danuta Mariola Jeziorska, James Raymond Hughes and James Davies and is headquartered in Oxford, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
GLYCOMIMETICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Tranzyme Pharma, Inc. (Canada) | Director/Board Member | ||
Kernel Management Partners Ltd.
![]() Kernel Management Partners Ltd. Investment ManagersFinance Kernel Management Partners Ltd. (Kernel Capital) is a venture capital firm founded in 1999 by Niall Olden. The firm is headquartered in Cork, Ireland. | Investment Managers | Private Equity Investor | |
APREA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Aprea Therapeutics AB
![]() Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
NOVIMMUNE SA | Medical/Nursing Services | Director/Board Member | |
Opsona Therapeutics Ltd.
![]() Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member | |
University of Oxford | College/University | Undergraduate Degree | |
Covagen AG
![]() Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Biotechnology | Director/Board Member | |
University of Cambridge | College/University | Doctorate Degree | |
Akinion Pharmaceuticals AB
![]() Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Corporate Officer/Principal |
Statistik
International
Schweden | 8 |
Vereinigtes Königreich | 7 |
Vereinigte Staaten | 7 |
Irland | 3 |
Schweiz | 3 |
Sektoral
Health Technology | 15 |
Finance | 4 |
Commercial Services | 3 |
Consumer Services | 3 |
Health Services | 2 |
Operativ
Director/Board Member | 14 |
Corporate Officer/Principal | 9 |
Private Equity Investor | 2 |
Independent Dir/Board Member | 1 |
Undergraduate Degree | 1 |